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INTRODUCTION
Autoinflammatory syndromes are a
group of disorders characterized by re-
current or chronic inflammation. The in-
flammation occurs spontaneously or
after minor triggers in the absence of au-
toantibodies and antigen-specific T-cells
(1,2). To date, at least eight genetically
distinct hereditary autoinflammatory
syndromes are known. Tumor necrosis
factor receptor–associated periodic syn-
drome (TRAPS) and the hyper-IgD and
periodic fever syndrome (HIDS) are two
of these syndromes. More recently, the
acquired disorder Schnitzler syndrome
(urticaria, periodic fever and parapro-
teinemia) has also been recognized as an
autoinflammatory syndrome (3,4). Al-
though the genetic mutations for the
hereditary autoinflammatory syndromes
are known, the pathogenesis of the recur-
rent inflammatory attacks is not fully
 explained. Symptomatic episodes are as-
sociated with increased serum concentra-
tions of both proinflammatory cytokines
(tumor necrosis factor [TNF]-α, inter-
leukin [IL]-6, IL-1β and interferon
[IFN]-γ) as well as antiinflammatory
 mediators (IL-1ra, sTNFR p55 and solu-
ble tumor necrosis factor receptor
[sTNFR] p75) (5–8). The current concept
is that IL-1β plays a central role in many
of these disorders (2,6,9,10).
Thus far, treatment of the recurrent
 inflammatory episodes in HIDS and
TRAPS has been difficult. Amyloidosis is
a serious complication of chronic or re-
current inflammation seen in these syn-
dromes (11–13). Therefore, it is important
to develop effective treatment options
that reduce clinical symptoms and the
acute-phase response in patients suffer-
ing from these syndromes. Recombinant
human IL-1 receptor antagonist
(rhIL-1ra, or anakinra) is effective in
 refractory TRAPS and HIDS and is re-
markably successful in Schnitzler syn-
drome. The success of this drug under-
scores the role of IL-1 in the pathogenesis
of these disorders. Despite its effective-
ness, daily painful subcutaneous injec-
tions and reactions at the injection site as
well as its short half-life remain a prob-
lem (3,14,15).
ITF2357 is an orally active histone
deacetylase (HDAC) inhibitor with a po-
tent antiinflammatory effect in preclinical
studies. In vitro studies show inhibition
of TNF-α, IFN-γ and IL-6 production and
IL-1β secretion (16,17). To establish
whether ITF2357 is able to modify the
clinical symptoms of patients with au-
toinflammatory syndromes and reduce
the acute-phase response in a safe and
noninvasive manner, we decided to per-
form an investigator-initiated open-label
pilot study.
PATIENTS AND METHODS
Adult patients with established
TRAPS, HIDS and Schnitzler syndrome
visiting the outpatient clinic of the Rad-
boud University Nijmegen Medical Cen-
tre were eligible for the study. Only pa-
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tients with severe active disease (one or
more attack every 8 wks or continuous
symptoms) were included. The local ethi-
cal committee gave permission for the
study, and all patients gave written in-
formed consent. The trial was registered
under number 2006-002415-27 in the
Clinical Trial Registry. Patients under the
age of 18 years, pregnant and lactating
women and patients with increased risk
for infection, current infection, renal fail-
ure (glomerular filtration rate <30 ml/
1.73 m2/min) or preexisting malignancy
were excluded from participation in the
study.
On a daily basis, patients were asked to
score the severity of their symptoms on a
scale of 1–10 on a symptom score list in
Dutch. This symptom score list was intro-
duced and discussed in more detail else-
where (14). In brief, the scores of one day
were added and this number (varying
from 0 to 130) is called the clinical score.
In continuous symptomatic patients,
complete remission required a clinical
score <5, the absence of fever (tempera-
ture <38.0°C) and normalization of C-re-
active peptide (CRP) (<10 mg/L) and
white blood cell count (<11 × 109/L). In
periodically symptomatic patients, com-
plete remission required the absence of
inflammatory attacks. The beginning of
an attack was defined by a clinical score
>20 and/or a temperature of ≥38.0°C.
The HDAC inhibitor ITF2357 was pro-
vided by the manufacturer (Italfarmaco
SpA, Cinisello Balsamo, Milan, Italy) as
50-mg capsules. Before start of the study
drug, biologicals such as anakinra and
etanercept had to be discontinued. 
Low-dose prednisolone (maximum
10 mg/day), nonsteroidal antiinflamma-
tory drugs, acetaminophen and oral an-
tihistaminic drugs were allowed. In con-
tinuous symptomatic patients, ITF2357
was started when patients were sympto-
matic after cessation of anakinra or
 etanercept, and ITF2357 was started in
patients with inflammatory attacks
when symptomatic or during an asymp-
tomatic period. The initial dose was 50
mg twice a day. If after a minimum of 4
d of treatment there was no complete re-
mission, the dose was increased to 50
mg ITF2357 three times a day. Based on
the available toxicology data at the time
of the study, treatment was not allowed
for >90 d.
Blood was taken from every patient
before the start of ITF2357. After start of
therapy, patients were seen on our out-
patient clinic on day 14, 42, 84 and 126
for evaluation of clinical symptoms,
physical examination and blood tests.
After cessation of the study drug, the pa-
tients were observed for at least 1 month
to monitor residual effects of the drug,
rebound phenomena and side effects. Pa-
tients were instructed to contact the in-
vestigator in case of any adverse effect. If
patients remained symptomatic during
treatment, more regular checkup visits
were scheduled.
Ex vivo production of cytokines (IL-6
and IL-1β) was measured as described
elsewhere (18). In short, the peripheral
blood mononuclear cell fraction was ob-
tained by density centrifugation of di-
luted heparinized blood (one part blood
to one part pyrogen-free saline) over
 Ficoll-Paque (Pharmacia Biotech,
 Uppsala, Sweden). Peripheral blood
mono nuclear cells were washed twice in
saline and suspended in culture me-
dium supplemented with 1% gentam-
icin, 1% L-glutamine, and 1% pyruvate.
The cells were counted in a hemocy-
tometer, and their number was adjusted
to 5 × 106 cells/mL. The 5 × 105 periph-
eral blood mononuclear cells in a volume
of 200 μL/well were incubated at 37°C in
round-bottom 96-well plates (Greiner,
Nurnberg, Germany) with 10 ng/mL
highly purified E. coli lipopolysaccharide
(Sigma) or culture medium alone. After
24 h of incubation, supernatants were
collected and stored at –20°C until as-
sayed. IL-1β and IL-6 concentrations
were measured in these supernatants by
commercial enzyme-linked immunosor-
bent assay kits (R&D Systems and
 Sanquin, respectively) according to the
manufacturer instructions.
RESULTS
One TRAPS patient, five patients with
Schnitzler syndrome and four patients
with HIDS were eligible. One Schnitzler
patient did not want to participate be-
cause of the necessity to discontinue
anakinra. One HIDS patient did not want
to participate because of the burden of
regular hospital visits. Patients with con-
tinuous symptoms who had to discon-
tinue or taper their standard medication
were admitted to our hospital for close
monitoring of the onset of symptoms.
Characteristics of the eight patients en-
rolled in the study are given in Table 1.
The duration of treatment and reasons
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Table 1. Patient characteristics before the start of ITF2357.
Mutation Attack frequency Attack duration Prior medication 
Patient Age/sex Disease (gene) (per month) (days) (mg/day)
1 24/F TRAPS C43Y (TNFRSF1A) 1.5 10–14 10 mg prednisolone, anakinra oda
2 64/M Schnitzler — Continuous — 25 mg prednisolone
3 61/F Schnitzler — Continuous — 100 mg anakinra
4 21/F HIDS V377I/V377I (MVK) 1.5 4–8 Anakinra od
5 61/M Schnitzler — Continuous — 100 mg anakinra, 5 mg levocetirizin
6 38/F HIDS V377I/G202R (MVK) 1.0 3–6 —
7 39/F HIDS V377I/del (MVK) 0.5 5–10 —
8 69/F Schnitzler — Continuous — —
aod, on demand.
for discontinuation are listed in Table 2.
As illustrative examples, we report three
patients in detail.
Patient 1 has been described previ-
ously as the first patient with TRAPS in
whom anakinra was shown to be effec-
tive (15). She had been treated intermit-
tently with anakinra and also 10 mg
prednisolone daily in the period before
enrollment. She started 100 mg ITF2357
(1.67 mg/kg) in a single dose each day
during an exacerbation, marked by a
temperature up to 38.7°C, serositis, myal-
gia, arthralgia, abdominal complaints, fa-
tigue and a migratory erythematous rash
(maximum clinical score 45 on day 1;
Figure 1). Initially, fever subsided (day
3), CRP level dropped from 159 to
50 mg/L (day 5) and symptoms im-
proved to a minimum clinical score of 20
(day 4). Physical examination showed no
abnormalities apart from a migratory
erythematous rash on the abdomen
(day 0–4) that disappeared during treat-
ment. After increasing the dose to
150 mg ITF2357 (2.5 mg/kg) on the
fourth day, she experienced side effects
in the form of abdominal complaints
with a maximum side effects score of 19
(nausea, vomiting and diarrhea) on the
ninth day, although these symptoms
could also indicate a TRAPS exacerba-
tion. The other inflammatory symptoms
also worsened and the clinical score rose
to a maximum of 35 on day 15 (myalgia,
fatigue, anorexia, arthralgia and serosi-
tis). This was accompanied by a rise in
CRP levels to 127 mg/L (day 15) and re-
currence of fever (maximum temperature
38.6°C on day 13). We concluded an ini-
tial partial response followed by an exac-
erbation and the occurrence of side ef-
fects associated with increasing the dose
of ITF2357. Therefore, ITF2357 was dis-
continued after 15 d of treatment.
Patient 8 was known to have Schnitzler
syndrome. Before enrollment in this study,
she had not received any medication. The
patient was started on 100 mg ITF2357
(1.33 mg/kg) in a single daily dose during
an exacerbation marked by urticaria, fa-
tigue, myalgia and arthralgia (maximum
clinical score 23 on day 2, maximal tem-
perature 38°C on day 1; Figure 2). Maxi-
mal CRP and serum amyloid A (SAA) lev-
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Table 2. Side effects and reasons for ITF2357 cessation.
Maximum ITF2357 Duration of Reason why ITF2357 
Patient dose (mg/day) ITF2357 use (days) Side effects Response was discontinued
1 150 15 Nausea, vomiting, diarrhea Partial Recurrence of attack and side effects 
(decreased CRP and leucocytes)
2 150 90 Abdominal pain, nausea Partial Complete course
3 150 6 No Aggravation of clinical symptoms 
(decreased CRP and leukocytes)
4 100 3 No More severe attack
5 150 51 Epigastric pain, nausea Partial Side effects
6 100 57 No Higher attack frequency and 
more severe attacks
7 100 42 No Higher attack frequency and 
more severe attacks
8 150 90 Partial Complete course
Figure 1. Clinical characteristics of patient
1 (TRAPS) during ITF2357 treatment. See
text for details.
Figure 2. Clinical characteristics of patient 8 (Schnitzler syndrome) during ITF2357 treat-
ment. See text for details.
els were 91 and 200 mg/L, respectively
(day 1 and 3). Immediately, the clinical
score dropped to ≤10, but since she kept
experiencing low-grade urticaria and
myalgia, the ITF2357 dose was raised to
150 mg (2 mg/kg) on day 13. CRP, SAA
concentrations and platelet counts re-
mained high throughout the treatment
period despite clinical improvement.
However, the leukocyte count normal-
ized (Figure 3). She experienced two ex-
acerbations with a clinical score >10.
There were no side effects. We concluded
a rapid initial response, but during 90 d,
the overall response was classified as a
partial response. After cessation, the pa-
tient experienced an exacerbation, which
responded to anakinra.
Patient 6 is a 38-year-old female with
HIDS who suffers from typical attacks
occurring once a month. Before partici-
pation in this study, she had not received
any medication. She started 100 mg
ITF2357 (1.33 mg/kg) in a single dose on
the first day of an HIDS attack (Figure 4).
The attack lasted 3 d, with a maximum
clinical score of 38 (sore throat, rhinitis,
myalgia, arthralgia, lymphadenopathy
and fatigue) and temperature of 39.1°C.
ITF2357 did not modulate attack severity
or duration. During treatment, she expe-
rienced two other HIDS attacks. The first
attack showed a clinical score of 42 (sore
throat, rhinitis, myalgia, arthralgia, lym-
phadenopathy, fatigue and rash) and
temperature of 40.1°C; the clinical score
of the second attack was 38 (sore throat,
rhinitis, myalgia, arthralgia, lymph -
adenopathy and fatigue), with a CRP of
20 mg/L and temperature of 39.7°C. She
felt that these two attacks were more se-
vere and longer than her usual attacks.
Therefore, ITF2357 was discontinued
after 57 d. We concluded no response.
No side effects were reported. During
the follow up of 5 months, she only ex-
perienced one attack (day 240 maximum
clinical score 26, temperature 38°C, CRP
level 74 mg/L).
Cytokines Studies
Measurements of the ex vivo produc-
tion of IL-1β and IL-6 showed highly
variable results with wide interindivid-
ual variation. No consistent pattern of in-
hibition was observed during prolonged
ITF2357 treatment (data not shown).
These observations are consistent with
phase I studies in volunteers (19), in
which the inhibition of cytokines showed
an inhibition during the first 4 h but a re-
turn to baseline cytokine production 12 h
after ingestion. In this study, we did not
take multiple samples during the day.
Side Effects
The side effects noted in our patients
are listed in Table 2. The major side ef-
fects were upper-abdominal complaints
with nausea and vomiting, which led to
premature cessation of treatment in two
patients (patients 1 and 5). Hematologi-
cal abnormalities and disturbances in
blood chemistry were not found.
DISCUSSION
In this open-label pilot study of the
HDAC inhibitor ITF2357 in eight pa-
tients with autoinflammatory disorders
(four patients with Schnitzler syndrome,
three with HIDS and one with TRAPS),
the effect of the drug was disappointing
compared with anakinra. We had high
expectations on the basis of the inhibi-
tion of IL-1β, TNF-α, IL-6 and IFN-γ but
not IL-1Ra ex vivo in volunteers (19). The
anticipated responses were expected to
be similar to those of anakinra but were
not. Nevertheless, there were objective
as well as subjective findings that
ITF2357 in some patients did initially re-
duce the severity of systemic inflamma-
tion. However, these were short-lived
and, as monotherapy, not sufficient to
replace parenteral administration of
anakinra and, in recent trials, antibodies
to IL-1β.
Although we observed partial remis-
sion in patients 1, 2, 5 and 8, there were
no responses in the other four. All three
HIDS patients were nonresponders and,
in fact, in HIDS patients, there was even
a tendency toward a higher attack fre-
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Figure 3. Leukocyte count in four patients
with Schnitzler syndrome before the start
of ITF2357, after 1 wk and after 3 months.
Figure 4. Clinical characteristics of patient 6 (TRAPS) during ITF2357 treatment. See text for
details.
quency and increasing attack severity
(patients 4, 6 and 7). In two patients, we
observed an effect on the markers of the
acute-phase response without signs of
clinical improvement (patients 1 and 3),
and in one patient (patient 8), there was
a partial response despite an ongoing
acute-phase response.
How can we explain the relatively dis-
appointing results? First, they may have
been caused by the selection of diseases.
From the successes of anakinra in Schnit-
zler syndrome and HIDS (and to a lesser
extent in TRAPS), the conclusion is that
these are typical IL-1β diseases (3,14,
15,20). Looking at the effects of ITF2357
on cytokine production ex vivo in volun-
teers, the conclusion may be drawn that
the effects on TNF, IL-6 and IFN-γ are
most impressive and occur at the level of
lipopolysaccharide-induced cytokine
synthesis. In the case of IL-1β, the reduc-
tion in this cytokine is not at the level of
gene expression or synthesis of the pre-
cursor but at the level of secretion (17).
Extrapolated to the situation in vivo, this
might mean that with an ongoing in-
flammatory drive, pro-IL-1β accumulates
intracellularly and may be even con-
verted to bioactive cytokine, without
being secreted when exposed to ITF2357.
Cells replete with IL-1β may act as cy-
tokine time bombs, releasing much
bioactive IL-1, for instance, when a con-
comitant stimulus arises.
Another explanation is that preceding
anakinra treatment in patients with
Schnitzler syndrome may have led to up-
regulated IL-1 receptor type 1, which
sensitizes cells as a target for cytokine ac-
tion. Patients 2 and 8 had never received
anakinra before ITF2357 and were the
only patients who completed the trial
with a satisfactory response. This hy-
pothesis may not apply to HIDS, since
two nonresponsive HIDS patients did
not receive anakinra in the 2 years before
participating in this study (6,7).
We did not detect major changes in ex
vivo production of IL-1β and IL-6 in the
days and weeks after the treatment. This
is consistent with the cytokine studies in
human volunteers, in which cytokine
production, especially of IL-6, was inhib-
ited over a period of 8–12 h, starting 2 h
after oral intake; 12 h after the intake of
the drug, the cytokine production was
again at baseline. Our studies do not
support a cumulative effect on cytokine
production.
The side effects of ITF2357 were rela-
tively mild, but led to cessation of the
drug in two patients (patients 1 and 5);
this should probably be viewed in face of
the relative ineffectiveness.
Where should we go from here? We
conclude that a larger (controlled) clini-
cal trial of ITF2357 monotherapy in the
autoinflammatory diseases is not war-
ranted. However, ITF2357 may be con-
sidered as a steroid-sparing drug in
combination with low-dose steroids. In
children with systemic-onset juvenile id-
iopathic arthritis, a disease highly re-
sponsive to IL-1β blockade, ITF2357 was
administered at a dose of 1.5 mg/kg in
two divided doses for 12 wks with excel-
lent safety (21). In that study, there was a
significant reduction in joint inflamma-
tion after 12 wks of therapy, which ex-
tended beyond cessation of the drug,
and there was a reduction in the ele-
vated white blood cell count and neu-
trophil count within 2 wks of initiation
of therapy (22), similar to some of the
patients studied in this report (see Fig-
ure 3). It appears that there is a limited
but consistent early response to ITF2357
in a reduction in objective markers of
systemic inflammation in both studies,
which might represent a reduction in ei-
ther IL-1β or IL-6.
From the present study, we conclude
that increasing the dose of ITF2357 to
>1.5 mg/kg appears to increase gastroin-
testinal side effects or even worsen dis-
ease severity. If ITF2357 is to be con-
sidered for chronic therapy, dosing of
1.5 mg/kg in two divided doses per day
is likely to minimize any side effects and
is required to enable prolonged use. In
the present study, however, the objective
as well as the clinical responses to an
oral HDAC inhibitor such as ITF2357 are
not as impressive as those after anakinra
or canakinumab administration.
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